Work

Prolonged hypereosinophilia associated with dupilumab for atopic dermatitis: A case series and review of literature

Year: 2024
Type: article
Abstract: Atopic dermatitis is a chronic, pruritic immune mediated inflammatory dermatosis characterized by a T helper 2 cell immune response.1 It has been treated with topical corticosteroids, oral immunosuppressants, and light phototherapy.2 However, dupilumab has been a breakthrough medication in treating atopic dermatitis. Dupilumab is a human monoclonal antibody that blocks interleukin 4 (IL-4) and interleukin 13 (IL-13) and has been shown to be safe and helpful in treating a variety of conditions.1 Blockade of IL-4 and IL-13 is effective in reducing the T helper 2 response, likely explaining the mechanism of action in treating atopic dermatitis.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $750
OpenAlex ID: W4402014679
FWCI: 0.954
Cites: 9
Cited by: 3
Related to: 10